

Fusion Proteins: Global Market

<https://marketpublishers.com/r/F989DB6393DFEN.html>

Date: October 2025

Pages: 127

Price: US\$ 4,650.00 (Single User License)

ID: F989DB6393DFEN

Abstracts

The report provides an overview of the global fusion proteins market and analyzes market trends. It includes global revenue (\$ million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented based on type, route of administration, application and region.

According to type, the market is segmented into cytokine traps, peptide-based fusion proteins, receptor-based fusion proteins and others. Based on application, the market is segmented into ophthalmic conditions, autoimmune diseases, metabolic disorders and hematological diseases. Regarding the route of administration, the market is segmented into intravenous, subcutaneous, intravitreal and others. The report also focuses on regional segmentation, including North America, Europe, Asia-Pacific and the Rest of the World, focusing on major countries in these regions.

The report focuses on the major driving trends and challenges that affect the market and vendor landscape. It analyzes environmental, social and corporate governance developments and discusses pipeline activities and emerging technologies related to the market. The report concludes with an analysis of the competitive landscape and industry structure. It also includes a dedicated section featuring company profiles with detailed information about leading companies. The scope of the report focuses on Fc-fusion protein products.

Report Includes

92 data tables and 51 additional tables

An overview of the global market for fusion proteins (genetically engineered recombinant therapeutics)

Analyses of the global market trends, with historical market revenue data from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030

Estimates of the market size and revenue growth prospects, along with a corresponding market share analysis by ligand type, route of administration, application, and region

Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables

Impact analysis of U.S. tariff laws, as well as use cases of AI adoption on the fusion proteins market

Insights derived from Porter's Five Forces model, as well as global supply chain analyses

Information on emerging trends and applications in diagnostics and research industries, ongoing research activities, newly approved products, and underlying clinical trials

Identification of the major companies involved in the production and modification of fusion proteins, and analysis of the competitive landscape of the market

Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies

A relevant patent analysis, featuring key granted and published patents

Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook

Profiles of the leading companies, including Regeneron Pharmaceuticals Inc., Bristol Myers Squibb Co., Lilly, Amgen Inc., and Sanofi

Summary:

The global market for fusion proteins is expected to grow from \$36.3 billion in 2025 to reach \$64.9 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.3% from 2025 to 2030.

Fusion proteins are an emerging area in protein engineering that combines an antibody with a desirable protein. The primary goals of fusion protein technology are to extend the duration of action and impart higher stability to protein drugs. These products have applications across therapeutic areas, including autoimmune, metabolic, oncologic, ophthalmic and cardiovascular conditions. The commercial success of many fusion proteins is driving the development of biosimilar versions of these proteins. Enbrel, Orencia, Trulicity, Eylea and Arcalyst were some of the best-selling fusion protein drugs in 2024.

Contents

CHAPTER 1 EXECUTIVE SUMMARY

Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion

CHAPTER 2 MARKET OVERVIEW

Overview
Technology Background
The Advantages of Fc-Fusion Proteins
Porter's Five Forces Analysis in the Fusion Proteins Market
Macroeconomic Factors Analysis
Impact of U.S. Tariffs
Government Policies on Drug Prices
Geopolitical Factors

CHAPTER 3 MARKET DYNAMICS

Market Dynamics
Market Drivers
Need to Improve Pharmacokinetic and Pharmacodynamic Properties of Existing Protein Drugs
Demand for Targeted Therapeutics
Market Restraints
Manufacturing Challenges
Side Effects and Immunogenicity Risks
Market Opportunities
Diagnostic Applications of Fusion Proteins
Label Expansions and Drugs with Extended Duration

CHAPTER 4 EMERGING TECHNOLOGIES AND PIPELINE ANALYSIS

Key Takeaways

Emerging Technologies

Antibody-Directed Enzyme Prodrug Therapy

Artificial Intelligence for Fusion Protein Engineering

Bifunctional Fusion Proteins for Cancer Therapy

Pipeline Analysis

CHAPTER 5 MARKET SEGMENTATION ANALYSIS

Segmental Breakdown

Market Analysis by Ligand Type

Key Takeaways

Cytokine Traps

Peptide-Based Fusion Proteins

Receptor-Based Fusion Proteins

Others

Market Analysis by Route of Administration

Key Takeaways

Subcutaneous

Intravitreal

Intravenous

Others

Market Analysis by Application

Key Takeaways

Ophthalmic Conditions

Autoimmune Diseases

Metabolic Disorders

Hematological Diseases

Others

Geographic Breakdown

Market Analysis by Region

Key Takeaways

North America

Europe

Asia-Pacific

Rest of the World

CHAPTER 6 COMPETITIVE INTELLIGENCE

Key Takeaways
Industry Structure
Company Share Analysis of the Fusion Proteins Market
Strategic Analysis

CHAPTER 7 SUSTAINABILITY IN THE FUSION PROTEINS MARKET: AN ESG PERSPECTIVE

Introduction to ESG
ESG Risk Ratings
Conclusion

CHAPTER 8 APPENDIX

Methodology
Sources
Acronyms
Company Profiles
AMGEN INC.
ASTRAZENECA
BAYER AG
BRISTOL-MYERS SQUIBB CO.
EVIVE BIOTECH
F. HOFFMANN-LA ROCHE LTD.
KINIKSA PHARMACEUTICALS
LILLY USA LLC.
MERCK & CO. INC.
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
REMEGEN
SAMSUNG BIOEPIS
SANDOZ GROUP AG
SANOFI
Emerging Start-ups/Market Disruptors

List Of Tables

LIST OF TABLES

- Summary Table : Global Fusion Proteins Market, by Region, Through 2030
- Table 1 : Active Clinical Trials in the Fusion Proteins Industry, 2025
- Table 2 : Global Fusion Proteins Market, by Ligand Type, Through 2030
- Table 3 : Global Cytokine Trap Fusion Proteins Market, by Region, Through 2030
- Table 4 : Global Peptide-Based Fusion Proteins Market, by Region, Through 2030
- Table 5 : Global Receptor-Based Fusion Proteins Market, by Region, Through 2030
- Table 6 : Global Other Ligand Type Fusion Proteins Market, by Region, Through 2030
- Table 7 : Global Fusion Proteins Market, by ROA, Through 2030
- Table 8 : Global Fusion Proteins Market for Subcutaneous ROA, by Region, Through 2030
- Table 9 : Global Fusion Proteins Market for Intravitreal ROA, by Region, Through 2030
- Table 10 : Global Fusion Proteins Market for Intravenous ROA, by Region, Through 2030
- Table 11 : Global Fusion Proteins Market for Other ROA, by Region, Through 2030
- Table 12 : Global Fusion Proteins Market, by Application, Through 2030
- Table 13 : Global Fusion Proteins Market for Ophthalmic Conditions, by Region, Through 2030
- Table 14 : Global Fusion Proteins Market for Autoimmune Diseases, by Region, Through 2030
- Table 15 : Global Fusion Proteins Market for Metabolic Disorders, by Region, Through 2030
- Table 16 : Global Fusion Proteins Market for Hematological Diseases, by Region, Through 2030
- Table 17 : Global Fusion Proteins Market for Other Applications, by Region, Through 2030
- Table 18 : Global Fusion Proteins Market, by Region, Through 2030
- Table 19 : North American Fusion Proteins Market, by Country, Through 2030
- Table 20 : North American Fusion Proteins Market, by Ligand Type, Through 2030
- Table 21 : North American Fusion Proteins Market, by ROA, Through 2030
- Table 22 : North American Fusion Proteins Market, by Application, Through 2030
- Table 23 : U.S. Fusion Proteins Market, by Ligand Type, Through 2030
- Table 24 : U.S. Fusion Proteins Market, by ROA, Through 2030
- Table 25 : U.S. Fusion Proteins Market, by Application, Through 2030
- Table 26 : Canadian Fusion Proteins Market, by Ligand Type, Through 2030
- Table 27 : Canadian Fusion Proteins Market, by ROA, Through 2030

- Table 28 : Canadian Fusion Proteins Market, by Application, Through 2030
- Table 29 : Mexican Fusion Proteins Market, by Ligand Type, Through 2030
- Table 30 : Mexican Fusion Proteins Market, by ROA, Through 2030
- Table 31 : Mexican Fusion Proteins Market, by Application, Through 2030
- Table 32 : European Fusion Proteins Market, by Country, Through 2030
- Table 33 : European Fusion Proteins Market, by Ligand Type, Through 2030
- Table 34 : European Fusion Proteins Market, by ROA, Through 2030
- Table 35 : European Fusion Proteins Market, by Application, Through 2030
- Table 36 : German Fusion Proteins Market, by Ligand Type, Through 2030
- Table 37 : German Fusion Proteins Market, by ROA, Through 2030
- Table 38 : German Fusion Proteins Market, by Application, Through 2030
- Table 39 : U.K. Fusion Proteins Market, by Ligand Type, Through 2030
- Table 40 : U.K. Fusion Proteins Market, by ROA, Through 2030
- Table 41 : U.K. Fusion Proteins Market, by Application, Through 2030
- Table 42 : French Fusion Proteins Market, by Ligand Type, Through 2030
- Table 43 : French Fusion Proteins Market, by ROA, Through 2030
- Table 44 : French Fusion Proteins Market, by Application, Through 2030
- Table 45 : Italian Fusion Proteins Market, by Ligand Type, Through 2030
- Table 46 : Italian Fusion Proteins Market, by ROA, Through 2030
- Table 47 : Italian Fusion Proteins Market, by Application, Through 2030
- Table 48 : Spanish Fusion Proteins Market, by Ligand Type, Through 2030
- Table 49 : Spanish Fusion Proteins Market, by ROA, Through 2030
- Table 50 : Spanish Fusion Proteins Market, by Application, Through 2030
- Table 51 : Rest of Europe Fusion Proteins Market, by Ligand Type, Through 2030
- Table 52 : Rest of Europe Fusion Proteins Market, by ROA, Through 2030
- Table 53 : Rest of Europe Fusion Proteins Market, by Application, Through 2030
- Table 54 : Asia-Pacific Fusion Proteins Market, by Country, Through 2030
- Table 55 : Asia-Pacific Fusion Proteins Market, by Ligand Type, Through 2030
- Table 56 : Asia-Pacific Fusion Proteins Market, by ROA, Through 2030
- Table 57 : Asia-Pacific Fusion Proteins Market, by Application, Through 2030
- Table 58 : Chinese Fusion Proteins Market, by Ligand Type, Through 2030
- Table 59 : Chinese Fusion Proteins Market, by ROA, Through 2030
- Table 60 : Chinese Fusion Proteins Market, by Application, Through 2030
- Table 61 : Japanese Fusion Proteins Market, by Ligand Type, Through 2030
- Table 62 : Japanese Fusion Proteins Market, by ROA, Through 2030
- Table 63 : Japanese Fusion Proteins Market, by Application, Through 2030
- Table 64 : South Korean Fusion Proteins Market, by Ligand Type, Through 2030
- Table 65 : South Korean Fusion Proteins Market, by ROA, Through 2030
- Table 66 : South Korean Fusion Proteins Market, by Application, Through 2030

Table 67 : Indian Fusion Proteins Market, by Ligand Type, Through 2030

Table 68 : Indian Fusion Proteins Market, by ROA, Through 2030

Table 69 : Indian Fusion Proteins Market, by Application, Through 2030

Table 70 : Australian Fusion Proteins Market, by Ligand Type, Through 2030

Table 71 : Australian Fusion Proteins Market, by ROA, Through 2030

Table 72 : Australian Fusion Proteins Market, by Application, Through 2030

Table 73 : Rest of Asia-Pacific Fusion Proteins Market, by Ligand Type, Through 2030

Table 74 : Rest of Asia-Pacific Fusion Proteins Market, by ROA, Through 2030

Table 75 : Rest of Asia-Pacific Fusion Proteins Market, by Application, Through 2030

Table 76 : RoW Fusion Proteins Market, by Subregion, Through 2030

Table 77 : RoW Fusion Proteins Market, by Ligand Type, Through 2030

Table 78 : RoW Fusion Proteins Market, by ROA, Through 2030

Table 79 : RoW Fusion Proteins Market, by Application, Through 2030

Table 80 : Recent Developments in the Fusion Proteins Market, 2022–2025

Table 81 : ESG Risk Rankings for Fusion Protein Drugs Companies, 2025

Table 82 : Report Information Sources

Table 83 : Abbreviations Used in the Global Fusion Proteins Market

Table 84 : Amgen Inc.: Company Snapshot

Table 85 : Amgen Inc.: Financial Performance, FY 2023 and 2024

Table 86 : Amgen Inc.: Product Portfolio

Table 87 : Amgen Inc.: News/Key Developments, 2022–2025

Table 88 : AstraZeneca: Company Snapshot

Table 89 : AstraZeneca: Financial Performance, FY 2023 and 2024

Table 90 : AstraZeneca: Product Portfolio

Table 91 : AstraZeneca: News/Recent Developments, 2023

Table 92 : Bayer AG: Company Snapshot

Table 93 : Bayer AG: Financial Performance, FY 2023 and 2024

Table 94 : Bayer AG: Product Portfolio

Table 95 : Bayer AG: News/Recent Developments, 2025

Table 96 : Bristol-Myers Squibb Co.: Company Snapshot

Table 97 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024

Table 98 : Bristol-Myers Squibb Co.: Product Portfolio

Table 99 : Bristol-Myers Squibb Co.: News/Key Developments, 2025

Table 100 : Evive Biotech: Company Snapshot

Table 101 : Evive Biotech: Product Portfolio

Table 102 : Evive Biotech: News/Key Developments, 2024–2025

Table 103 : F. Hoffmann-La Roche Ltd.: Company Snapshot

Table 104 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024

Table 105 : F. Hoffmann-La Roche Ltd.: Product Portfolio

- Table 106 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
- Table 107 : Kiniksa Pharmaceuticals: Company Snapshot
- Table 108 : Kiniksa Pharmaceuticals: Financial Performance, FY 2023 and 2024
- Table 109 : Kiniksa Pharmaceuticals: Product Portfolio
- Table 110 : Kiniksa Pharmaceuticals: News/Key Developments, 2022
- Table 111 : Lilly USA LLC.: Company Snapshot
- Table 112 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
- Table 113 : Lilly USA LLC.: Product Portfolio
- Table 114 : Lilly USA LLC.: News/Key Developments, 2025
- Table 115 : Merck & Co. Inc.: Company Snapshot
- Table 116 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
- Table 117 : Merck & Co. Inc.: Product Portfolio
- Table 118 : Merck & Co. Inc.: News/Key Developments, 2023
- Table 119 : Pfizer Inc.: Company Snapshot
- Table 120 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
- Table 121 : Pfizer Inc.: Product Portfolio
- Table 122 : Pfizer Inc.: News/Key Developments, 2022
- Table 123 : Regeneron Pharmaceuticals Inc.: Company Snapshot
- Table 124 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
- Table 125 : Regeneron Pharmaceuticals Inc.: Product Portfolio
- Table 126 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022–2023
- Table 127 : RemeGen: Company Snapshot
- Table 128 : RemeGen: Financial Performance, FY 2023 and 2024
- Table 129 : RemeGen: Product Portfolio
- Table 130 : RemeGen: News/Key Developments, 2025
- Table 131 : Samsung Bioepis: Company Snapshot
- Table 132 : Samsung Bioepis: Product Portfolio
- Table 133 : Samsung Bioepis: News/Key Developments, 2025
- Table 134 : Sandoz Group AG: Company Snapshot
- Table 135 : Sandoz Group AG: Financial Performance, FY 2023 and 2024
- Table 136 : Sandoz Group AG: Product Portfolio
- Table 137 : Sandoz Group AG: News/Key Developments, 2025
- Table 138 : Sanofi: Company Snapshot
- Table 139 : Sanofi: Financial Performance, FY 2023 and 2024
- Table 140 : Sanofi: Product Portfolio
- Table 141 : Sanofi: News/Key Developments, 2024
- Table 142 : List of a Few Emerging Startups

List Of Figures

LIST OF FIGURES

- Summary Figure : Global Market Shares of Fusion Proteins, by Region, 2024
- Figure 1 : Characteristics of Therapeutic Fusion Proteins
- Figure 2 : Porter's Five Forces Analysis: Fusion Proteins Market
- Figure 3 : Global Market Dynamics of Fusion Proteins
- Figure 4 : Emerging Technologies in the Fusion Proteins Market
- Figure 5 : Global Market Shares of Fusion Proteins, by Ligand Type, 2024
- Figure 6 : Global Market Shares of Fusion Proteins, by ROA, 2024
- Figure 7 : Global Market Shares of Fusion Proteins, by Application, 2024
- Figure 8 : Global Market Shares of Fusion Proteins, by Region, 2024
- Figure 9 : North American Market Shares of Fusion Proteins, by Country, 2024
- Figure 10 : European Market Shares of Fusion Proteins, by Country, 2024
- Figure 11 : Asia-Pacific Market Shares of Fusion Proteins, by Country, 2024
- Figure 12 : RoW Market Shares of Fusion Proteins, by Subregion, 2024
- Figure 13 : Global Fusion Proteins Market Share Analysis, by Company, 2024
- Figure 14 : Key ESG Metrics of Fusion Proteins Companies
- Figure 15 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024
- Figure 16 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
- Figure 17 : AstraZeneca: Revenue Share, by Business Unit, FY 2024
- Figure 18 : AstraZeneca: Revenue Share, by Country/Region, FY 2024
- Figure 19 : Bayer AG: Revenue Share, by Business Unit, FY 2024
- Figure 20 : Bayer AG: Revenue Share, by Country/Region, FY 2024
- Figure 21 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
- Figure 22 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
- Figure 23 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
- Figure 24 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
- Figure 25 : Kiniksa Pharmaceuticals: Revenue Share, by Business Unit, FY 2024
- Figure 26 : Lilly USA LLC.: Revenue Share, by Business Unit, FY 2024
- Figure 27 : Lilly USA LLC.: Revenue Share, by Country/Region, FY 2024
- Figure 28 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2024
- Figure 29 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2024
- Figure 30 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
- Figure 31 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
- Figure 32 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2024
- Figure 33 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2024

2024

Figure 34 : RemeGen: Revenue Share, by Country/Region, FY 2024

Figure 35 : Sandoz Group AG: Revenue Share, by Business Unit, FY 2024

Figure 36 : Sandoz Group AG: Revenue Share, by Country/Region, FY 2024

Figure 37 : Sanofi: Revenue Share, by Country/Region, FY 2024

I would like to order

Product name: Fusion Proteins: Global Market

Product link: <https://marketpublishers.com/r/F989DB6393DFEN.html>

Price: US\$ 4,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F989DB6393DFEN.html>